Everything below concerns Angiotensin IV analog. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-05-05. Where a claim depends on a specific study, the study is described rather than over-claimed.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Modeled on angiotensin IV |
| Common synonyms | PNB-0408; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Research codes vary by supplier |
| Appearance | White to off-white powder | Typical for lyophilized peptides |
| Solubility | Soluble in organic solvents; limited in water | Formulation dependent |
| Typical storage | −20 °C, desiccated, protected from light | Stability depends on purity and container |
Identity and purity of dihexa samples are typically assessed with high-performance liquid chromatography and mass spectrometry. These methods can confirm molecular mass and estimate the presence of impurities. However, a certificate of analysis from a supplier is not a guarantee of independent testing. Researchers often require in-house verification before using a peptide in experiments. For solid samples, appearance, solubility, and chromatographic profile provide additional checks. Nuclear magnetic resonance may be used for structural confirmation when available.
Dihexa is commonly handled as a lyophilized powder in laboratory settings. Storage at -20 °C in a desiccated, light-protected container is typical for peptides. Repeated freeze-thaw cycles can degrade the material, so aliquoting is often recommended. Aqueous solutions may be less stable than organic stocks and should be prepared fresh when possible. Personnel should follow institutional safety procedures and avoid uncontrolled exposure. Because human effects are not well characterized, handling precautions are prudent.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
FS−SF → S=SF2 Decomposing to sulfur tetrafluoride and sulfur when heated to 180 °C: 2 S2F2 → SF4 + 3 S Hydrolysis: 2 S2F2 + 2 H2O → SO2 + 3 S + 4 HF Reacting with sulfuric acid at 80 °C: S2F2 + 3 H2SO4 → 5 SO2 + 2 HF + 2 H2O Reacting with sodium hydroxide: 2 S2F2 + 6 NaOH → Na2SO3 + 3 S + 4 NaF + 3 H2O Reacting with oxygen at high pressure, using nitrogen dioxide as a catalyst: 2 S2F2 + 5 O2 → SOF4 + 3 SO3
== External links == 16S rRNA, BioMineWiki Archived 2019-04-27 at the Wayback Machine Ribosomal Database Project II Archived 2020-08-19 at the Wayback Machine Ribosomal+RNA at the U.S. National Library of Medicine Medical Subject Headings (MeSH) SILVA rRNA Database Project (also includes Eukaryotes (18S) and LSU (23S/28S)) Video: rRNA: sequence, function & synthesis Halococcus morrhuae (archaebacterium) 5S rRNA
=== China === Journalist Joshua Kurlantzick writes that China has been engaging in a "charm offensive" in the 21st century to improve relations with many other countries, especially in the developing world. Kurlantzick contends that the Chinese government has leveraged the construction of large works of architecture abroad to better its standing with these countries. He also criticizes many of these projects, such as large-sized buildings and government ministries, as white-elephant projects. Kurlantzick cites examples of Chinese-led construction in Mozambique and East Timor as examples.
=== Gr–Gu === Sam Granick (1909–1977). American biochemist at the Rockefeller University, known for his studies of ferritin and iron metabolism. Member Natl. Acad. Sci. USA. David E. Green (1910–1983). American biochemist at the University of Wisconsin, pioneer in the study of enzymes involved in oxidative phosphorylation. Member Natl. Acad. Sci. USA. Rowena Green Matthews (b. 1938). American biochemist at the University of Michigan Ann Arbor, working on the role of organic cofactors of enzymes, especially folic acid and cobalamin. Member Natl. Acad. Sci. USA. Lewis Joel Greene (b. 1934), American-Brazilian biochemist at the University of São Paulo, known for studies of protein chemistry. François Gros (1925–2022). French biologist and pioneer of cellular biochemistry at the French Academy of Sciences. Kun-Liang Guan (b. 1963). Chinese-American biochemist at the University of Michigan who works on gene regulation. F. Peter Guengerich (b. 1949). Biochemist and toxicologist at Vanderbilt University, working on cytochromes P450, DNA damage and carcinogenesis, and drug metabolism. Note. His personal Wikipedia page is very uninformative. Joan Guinovart (1947–2025). Spanish biochemist at the Institute for Research in Biomedicine (IRB Barcelona) known for studies of glycogen. Irwin Gunsalus (1912–2008). American biochemist at the University of Illinois, who discovered lipoic acid. He coauthored The Bacteria: A Treatise on Structure and Function with Roger Y. Stanier, a highly influential five-volume work. Member Natl. Acad. Sci. USA. Herbert Gutfreund FRS (1921–2021).
=== From mechanical blood processing during surgery === In some surgical procedures (especially some heart operations) where substantial blood loss is expected, machinery is used for intraoperative blood salvage. A centrifuge process takes blood from the patient, washes the red blood cells with normal saline, and returns them to the patient's blood circulation. Hemolysis may occur if the centrifuge rotates too quickly (generally greater than 500 rpm)—essentially this is hemolysis occurring outside of the body. Increased hemolysis occurs with massive amounts of sudden blood loss, because the process of returning a patient's cells must be done at a correspondingly higher speed to prevent hypotension, pH imbalance, and a number of other hemodynamic and blood level factors. Modeling of fluid flows to predict the likelihood of red cell membrane rupture in response to stress is an active area of research.
Sources: en.wikipedia.org
=== Mechanism of action === Dofetilide works by selectively blocking the rapid component of the delayed rectifier outward potassium current (IKr). This causes the refractory period of atrial tissue to increase, hence its effectiveness in the treatment of atrial fibrillation and atrial flutter. Dofetilide does not affect dV/dTmax (the slope of the upstroke of phase 0 depolarization), conduction velocity, or the resting membrane potential.
Biochemistry laboratories often use in vitro studies to explore ATP-dependent molecular processes. ATP analogs are also used in X-ray crystallography to determine a protein structure in complex with ATP, often together with other substrates. Enzyme inhibitors of ATP-dependent enzymes such as kinases are needed to examine the binding sites and transition states involved in ATP-dependent reactions. Most useful ATP analogs cannot be hydrolyzed as ATP would be; instead, they trap the enzyme in a structure closely related to the ATP-bound state. Adenosine 5′-(γ-thiotriphosphate) is an extremely common ATP analog in which one of the gamma-phosphate oxygens is replaced by a sulfur atom; this anion is hydrolyzed at a dramatically slower rate than ATP itself and functions as an inhibitor of ATP-dependent processes. In crystallographic studies, hydrolysis transition states are modeled by the bound vanadate ion. Caution is warranted in interpreting the results of experiments using ATP analogs, since some enzymes can hydrolyze them at appreciable rates at high concentration.
Side effects of midazolam in the elderly are listed above. People experiencing amnesia as a side effect of midazolam are generally unaware their memory is impaired, unless they had previously known it as a side effect. Long-term use of benzodiazepines has been associated with long-lasting deficits in memory, and show only partial recovery six months after stopping benzodiazepines. It is unclear whether full recovery occurs after longer periods of abstinence. Benzodiazepines can cause or worsen depression. Paradoxical excitement occasionally occurs with benzodiazepines, including a worsening of seizures. Children and elderly individuals or those with a history of excessive alcohol use and individuals with a history of aggressive behavior or anger are at increased risk of paradoxical effects. Paradoxical reactions are particularly associated with intravenous administration. After nighttime administration of midazolam, residual 'hangover' effects, such as sleepiness and impaired psychomotor and cognitive functions, may persist into the next day. This may impair the ability of users to drive safely and may increase the risk of falls and hip fractures. Sedation, respiratory depression and hypotension due to a reduction in systematic vascular resistance, and an increase in heart rate can occur. If intravenous midazolam is given too quickly, hypotension may occur. A "midazolam infusion syndrome" may result from high doses, is characterised by delayed arousal hours to days after discontinuation of midazolam, and may lead to an increase in the length of ventilatory support needed.
== Further reading == Davidson JA, Sloan L (January 2017). "Fixed-Dose Combination of Canagliflozin and Metformin for the Treatment of Type 2 Diabetes: An Overview". Adv Ther. 34 (1): 41–59. doi:10.1007/s12325-016-0434-2. PMC 5216068. PMID 27854055.
Sources: en.wikipedia.org
It is a synthetic peptide analog of angiotensin IV studied mainly in laboratory and animal research. It is not an approved medicine. Human clinical data are limited.
It is generally not regulated as a dietary supplement. Products are often sold as research chemicals. That status affects purity, labeling, and legal availability.
Dihexa itself is not a standard endogenous peptide. It is synthesized and modeled on angiotensin IV. Angiotensin IV occurs naturally as a fragment of angiotensin II.
Dihexa is a synthetic peptide analog of angiotensin IV, often described as an HGF mimetic in research literature. It is studied for effects on synaptic connectivity in laboratory models. It is not an approved medication.